Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56911—Bacteria
  • G01N33/56955—Bacteria involved in periodontal diseases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
  • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
  • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
  • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
  • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
  • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
  • G01N2333/96486—Metalloendopeptidases (3.4.24)

Definitions

• Periodontitis is characterized, in part, by abnormal and excessive degradation of the periodontal organic matrix.
• This matrix includes the gingiva, periodontal ligament, cementum and alveolar bone. At least a portion of the destruction of the matrix is mediated by the overproduction of matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases. MMPs also facilitate bone resorption by degrading the osteoid (i.e.. the non- mineralized and newly-synthesized bone matrix), then degrading the matrix.
• MMPs matrix metalloproteinases
• the invention includes a method for treating periodontitis in a mammal in need thereof comprising contacting a cell in the mouth of the mammal with an agent that down- regulates at least one matrix metalloproteinase selected from the group consisting of MMP-9 and MMP- 13, wherein the down-regulation of the metalloproteinase correlates with a reduction in at least one symptom associated with periodontitis.
• the invention also includes a method of identifying a compound useful in treating periodontitis in a mammal, the method comprising contacting a cell with a test compound and determining whether the test compound down-regulates at least one matrix metalloproteinase selected from the group consisting of MMP-9 and MMP- 13, wherein the down-regulation of at least one of the matrix metalloproteinases is an indication that the test compound is useful to treat periodontitis.
• the invention also includes a method of treating periodontitis in a mammal in need thereof comprising administering to the oral cavity of the mammal an oral composition comprising 2,4,4'-trichloro-2'-hydroxydiphenyl ether in an amount which is effective to down-regulate at least one matrix metalloproteinase in the oral cavity of the mammal, the matrix metalloproteinase being selected from the group consisting of MMP-9 and MMP-13, wherein the down-regulation of the matrix metalloproteinase results in the treatment of periodontitis in the mammal.
• the invention further includes a method of reducing a pathological excess of matrix metalloproteinase activity in the oral cavity of a mammal in need thereof comprising administering to the oral cavity of the mammal an oral composition comprising 2,4,4'- trichloro-2'-hydroxydiphenyl ether in an amount which is effective for reducing the matrix metalloproteinase activity in the oral cavity of the mammal, the matrix metalloproteinase being selected from the group consisting of MMP-9 and MMP-13. wherein the inhibition of the matrix metalloproteinase activity results in the inhibition of an excessive degradation of connective tissue matrix protein components.
• the invention includes a method of reducing a pathological excess of matrix metalloproteinase in the oral cavity of a mammal in need thereof comprising administering to the oral cavity of the mammal an oral composition comprising 2,4,4'-trichloro-2 " - hydroxydiphenyl ether in an amount which is effective for reducing the matrix metalloproteinase level in the oral cavity of the mammal, wherein the inhibition of the matrix metalloproteinase level results in the inhibition of an excessive degradation of connective tissue matrix protein components, and wherein the matrix metalloproteinase is selected from the group consisting of MMP-9 and MMP-13.
• a method includes an oral composition comprising 0-36% by weight of a siliceous polishing agent; 0.25%-0.35% by weight of a substantially water insoluble noncationic antibacterial agent selected from the group consisting of halogenated diphenyl ethers, halogenated salicylanilides, benxoic esters, halogenated carbanilides and phenolic compounds; and an effective amount of 0.01%-4.0% by weight of an antibacterial- enhancing agent which enhances delivery and adherence of said antibacterial agent to, and the retention thereof on, oral tooth and gum surfaces, wherein said antibacterial-enhancing agent is (i) a copolymer of maleic acid or anhydride with another inert ethylenically unsaturated polymerizable monomer or (ii) poly (beta-styrene-phosphonic acid) or poly (alpha-styrenephosphonic acid) polymer or a copolymer of either styrenephosphonic
• a method includes an oral composition comprising an effective anticalculus amount of at least one water-soluble linear molecularly-dehydrated polyphosphate salt as an essential anticalculus agent, an effective antiplaque amount of a substantially water insoluble noncationic antibacterial compound as an essential antiplaque agent, and, optionally, an amount of a fluoride ion-providing source sufficient to supply 25 ppm to 5,000 ppm of fluoride ions.
• 2,4,4'-trichloro-2'-hydroxydiphenyl ether is present in a composition at a concentration from 1 ppm to 100 ppm.
• an oral composition is a mouthwash or a mouthrinse.
• a mouthwash or mouthrinse does not comprise a siliceous polishing agent.
• Figure 1 illustrates the effect of 2,4,4'-trichloro-2'-hydroxydiphenyl ether on TNF ⁇ - induced MMP-9 production of monocytes.
• Figure 2 illustrates the effect of 2,4,4'-trichloro-2'-hydroxydiphenyl ether on PTH- induced MMP- 13 production of osteoblasts.
• Figure 3 illustrates the effect of a dentifrice of the present invention on PTH-induced MMP- 13 production of osteoblasts.
• MMP-8 Three major destructive MMPs in periodontitis are MMP-8, MMP-9, and MMP-13.
• MMP-8 and MMP- 13 are collagenases, and MMP-9 is a gelatinase. All three enzymes can be found in diseased periodontal tissue and gingival crevicular fluid. The levels of these enzymes are positively correlated to periodontitis clinical indices. That is, elevated, or "above normal" levels of at least one of MMP-8, MMP-9, and MMP-13 is an indication of periodontits.
• the measurements may be made of MMP-8.
• an oral composition comprising 2,4,4'- trichloro-2'-hydroxydiphenyI ether (triclosan) can be used to reduce the levels of at least one of MMP-8, MMP-9, and MMP-13 in the oral cavity of a mammal.
• the oral composition is a dentifrice.
• the oral composition comprises a mouthwash, a patch, or a gel, among other things.
• an antibacterial compound can be used to reduce the levels of at least one of MMP-8, MMP-9, and MMP-13 in the oral cavity of a mammal.
• periodontitis refers to abnormal and excessive degradation of the periodontal organic matrix, including the gingiva, periodontal ligament, cementum and alveolar bone.
• the clinical manifestation of periodontitis includes, but is not limited to, gingival recession, pocket formation, loss of matrix attachment, tooth and bone loss.
• Periodontitis may be characterized as early periodontitis, moderate periodontitis or advanced periodontitis. However, periodontitis should not be limited to only those symptoms and sequelae set forth herein, as will be understood by the skilled artisan.
• Advanced periodontitis is clinically manifested by one or more of: bleeding upon probing; the presence of pockets (over 6 mm); attachment loss (over 6 mm); grade II and/or grade III furcation invasion areas; class II and/or class III tooth mobility; bone loss (e.g., horizontal and/or vertical); and loss of over 1/3 of supporting alveolar bone (i.e., crown to root ratio of 2: 1 or more).
• Periodontitis is divided into subdivisions including, but not limited to: adult periodontitis (e.g., plaque-associated); early-onset periodontitis (e.g., prepubertal, juvenile, rapidly progressive and the like); periodontitis associated with systemic diseases; necrotizing ulcerative periodontitis; refractory periodontitis; peri-implantitis and the like.
• adult periodontitis e.g., plaque-associated
• early-onset periodontitis e.g., prepubertal, juvenile, rapidly progressive and the like
• periodontitis associated with systemic diseases necrotizing ulcerative periodontitis
• refractory periodontitis peri-implantitis and the like.
• treatment of periodontitis will be understood to include the prevention of periodontitis in a mammal, as well as inhibition of the progression of one or more preexisting conditions associated with periodontitis in a mammal.
• the terms “inhibit” and “inhibition” refer to a partial inhibition or a complete inhibition of periodontitis compared to the condition without treatment, such that therapeutic treatment and/or prophylaxis results.
• Treatment of periodontitis according to the invention therefore includes the reduction, inhibition of, improvement of, lessening, diminishment, cessation, or elimination of one or more of the symptoms and/or sequelae set forth herein.
• pathological excess refers to activity above an accepted normal level.
• a “pathological excess” of matrix metalloproteinase activity is a level of matrix metalloproteinase activity that is above the level normally found in a non-disease state.
• a “pathological excess of matrix metalloproteinase activity” is a level of matrix metalloproteinase activity associated with periodontitis.
• downstream regulate refers to a decrease in enzymatic activity, a decrease in the level of enzymatic activity, a decrease in the level of protein and/or nucleic acid encoding such protein, or a decrease in the biochemical effect of the presence of a protein, such as one or more of MMP-8, MMP-9, and MMP-13.
• the invention provides a method of reducing a pathological excess of at least one of MMP-8, MMP-9 and MMP-13 in the oral cavity of a mammal in need thereof comprising administering to the oral cavity of the mammal an oral composition comprising 2.4,4'-trichloro-2'-hydroxydiphenyl ether in an amount which is effective for reducing the matrix metalloproteinase level in the oral cavity of the mammal, wherein the inhibition of the matrix metalloproteinase level results in the inhibition of an excessive degradation of connective tissue matrix protein components.
• An MMP such as MMP-8, MMP-9 or MMP- 13, may be reduced in the oral cavity in one of multiple ways, as set forth herein.
• an MMP may be reduced in the oral cavity by down-regulating the MMP at the nucleic acid level, as set forth elsewhere herein. Such a reduction may result in a reduction in one or more of the nucleic acid encoding the MMP (e.g., mRNA) and the MMP enzyme expressed into the oral cavity.
• Reduction of the mRNA encoding an MMP for example, may be effected by one or more of multiple techniques, as will be understood by the skilled artisan, when armed with the disclosure set forth herein.
• an MMP may be reduced in the oral cavity by directly reducing the amount of MMP enzyme.
• Reduction of MMP enzyme may be effected by one or more of multiple techniques, as will be understood by the skilled artisan, when armed with the disclosure set forth herein. Examples include inhibition of the enzyme via a small molecule inhibitor, inhibition via a natural or biologically-derived molecule, proteolytic degradation of the enzyme, and affinity-based clearance of the enzyme from the oral cavity, among others.
• An agent that reduces one or more of MMP-8, MMP-9 or MMP- 13 may be an agent as described herein, such as 2,4,4'-trichloro-2'-hydroxydiphenyl ether (TRICLOSAN), or it may be another antibacterial agent.
• an agent may be something other than an antibacterial agent.
• the invention provides methods of treating an individual afflicted with periodontitis.
• a method for reducing a pathological excess of matrix metalloproteinase activity in the oral cavity of a mammal in need thereof comprising administering to the oral cavity of the mammal an oral composition comprising 2,4,4'-trichloro-2'-hydroxydiphenyl ether in an amount which is effective for reducing the matrix metalloproteinase activity of at least one of MMP-8, MMP-9 and MMP- 13 in the oral cavity of the mammal, wherein the inhibition of the matrix metalloproteinase activity results in the inhibition of an excessive degradation of connective tissue matrix protein components.
• administering to the oral cavity of the mammal an oral composition comprising 2,4,4'-trichloro-2 ' -hydroxydiphenyl ether is done in an amount which is effective for reducing the level of at least one of MMP-8, MMP-9 and MMP- 13 in the oral cavity of the mammal, wherein the reduction of the level of the matrix metalloproteinase results in an reduction in the overall enzymatic activity of the metalloproteinase, resulting in the inhibition of excessive degradation of connective tissue matrix protein components.
• a pathological excess of one or more MMPs may be reduced as described elsewhere herein with respect to reduction in the amount of MMP in the oral cavity of a mammal. That is, an MMP may be reduced at one or both of the nucleic acid and protein levels. As described elsewhere herein, the reduction in a pathological excess of one or more such MMP ' s can provide treatment of periodontitis in a mammal.
• the invention provides a method of reducing the activity of at least one of MMP-8, MMP-9 and MMP- 13 in the oral cavity of a mammal in need thereof, comprising administering to the oral cavity of the mammal an oral composition comprising 2,4,4'-trichloro-2'-hydroxydiphenyl ether in an amount which is effective for reducing the matrix metalloproteinase level in the oral cavity of the mammal, wherein the inhibition of the matrix metalloproteinase level results in the inhibition of an excessive degradation of connective tissue matrix protein components.
• the activity of one or more MMPs may be reduced as described elsewhere herein with respect to reduction in the amount of MMP protein in the oral cavity of a mammal.
• an MMP may be reduced at one or both of the nucleic acid and protein levels, thereby reducing the activity of the MMPs in the oral cavity, either by directly reducing the activity of the MMP or indirectly, by reducing the level of MMP protein and/or nucleic acid.
• the invention provides methods of treating periodontitis in a mammal in need thereof comprising contacting a cell in the oral cavity of the mammal with an agent that down-regulates one or both of at least one of MMP-8, MMP-9 and MMP-13.
• the down-regulation of the metalloproteinase correlates with a reduction in at least one symptom associated with periodontitis.
• An MMP such as MMP-8, MMP-9 or MMP- 13 may be down-regulated at the nucleic acid level.
• an MMP may be down-regulated according to the invention by down-regulating the mRNA encoding the MMP.
• a method of the invention comprises contacting the oral cavity of a mammal with an agent that down-regulates one or more of MMP-8, MMP-9 or MMP-13.
• An agent that down-regulates one or more of MMP-8, MMP-9 or MMP- 13 may be an agent as described herein, such as TRICLOSAN, or it may be another antibacterial agent. In another aspect, an agent may be something other than an antibacterial agent.
• the invention provides methods of treating an individual afflicted with periodontitis.
• the invention provides a method of treating periodontitis in a mammal in need thereof.
• a method of treating periodontitis in a mammal in need thereof comprises administering to the oral cavity of the mammal an oral composition comprising 2,4,4'-trichloro-2'-hydroxydiphenyl ether in an amount which is effective to down-regulate at least one of MMP-8, MMP-9 and MMP-13, wherein the down-regulation of matrix metalloproteinase results in the treatment of periodontitis in the mammal.
• a method of treating periodontitis in a mammal in need thereof comprises administering to the oral cavity of the mammal an oral composition comprising 2,4,4'- trichloro-2'-hydroxydiphenyl ether in an amount which is effective to reduce the level of at least one of MMP-8, MMP-9 and MMP- 13. wherein the reduction in the level of matrix metalloproteinase results in the treatment of periodontitis in the mammal.
• a method of treating periodontitis in a mammal in need thereof comprises administering to the oral cavity of the mammal an oral composition comprising 2,4,4'- trichloro-2'-hydroxydiphenyl ether in an amount which is effective to reduce the level of activity of at least one of MMP-8, MMP-9 and MMP-13, wherein the reduction in the level of matrix metalloproteinase activity results in the treatment of periodontitis in the mammal.
• the activity of one or more MMPs may be reduced as described elsewhere herein with respect to reduction in the amount of MMP in the oral cavity of a mammal.
• an MMP may be reduced at one or both of the nucleic acid and protein levels, thereby reducing the activity of the MMPs in the oral cavity.
• the down- regulation of an MMP or the reduction in the level of an MMP may be affected by action at either or both of the nucleic acid and protein levels, as described in detail elsewhere herein.
• the invention provides a method of identifying a compound useful in treating periodontitis in a mammal in need thereof, comprising contacting a cell with a test compound and determining whether the test compound down-regulates one or both of at least one of MMP-8, MMP-9 and MMP-13.
• a method of treating periodontitis comprises administering an agent identified by a screening assay described herein, or a combination of agents that inhibit one or more markers of periodontitis, wherein at least one of the agents is an agent identified by a screening assay described herein.
• the invention provides a method for treatment of periodontitis, comprising the step of administering a therapeutically effective amount of an agent which inhibits the periodontal disease and/or periodontal disorder to a subject in need of such treatment.
• a therapeutically effective amount of agent i.e., an effective dosage
• a therapeutically effective amount of agent ranges from 0.001 to 30 mg/kg body weight, preferably 0.01 to 25 mg/kg body weight, more preferably 0.1 to 20 mg/kg body weight, and even more preferably 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
• treatment of a subject with a therapeutically effective amount of an inhibitor can include a single treatment or, preferably, can include a series of treatments. It will also be appreciated that the effective dosage of in used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result from the results of diagnostic assays as described herein.
• An exemplary method for detecting the presence or absence of periodontitis in a mammal comprises obtaining a biological sample from the oral cavity of a test subject and contacting the biological sample with a compound or an agent capable of detecting one or more of the markers of periodontitis (i.e.
• an agent for detecting marker mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to marker mRNA or genomic DNA.
• the nucleic acid probe can be, for example, a full-length marker nucleic acid or a portion thereof.
• a marker of periodontitis is used as a way to detect the marker (i.e. MMP-8, MMP-9, or MMP- 13 activity). Any assay now known or later developed to detect the activity of a marker is encompassed herein.
• an agent for detecting marker peptide is an antibody capable of binding to a marker peptide, such as an antibody with a detectable label.
• Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab').sub.2) can be used.
• the term "labeled,” with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
• biological sample is intended to include tissues, cells and biological fluids isolated from the oral cavity of a subject, as well as tissues, cells and fluids present within the oral cavity of a subject. That is, the detection method of the invention can be used to detect marker mRNA. peptide (e.g., protein), or genomic DNA in a biological sample in vitro as well as in vivo.
• in vitro techniques for detection of marker mRNA include Northern hybridizations and in situ hybridizations.
• in vitro techniques for detection of marker peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
• In vitro techniques for detection of marker genomic DNA include Southern hybridizations.
• In vivo techniques for detection of marker peptide include introducing into the oral cavity of a subject a labeled anti-marker antibody.
• the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
• the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting marker peptides, mRNA, or genomic DNA, such that the presence of marker peptide, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of marker peptides, mRNA or genomic DNA in the control sample with the presence of marker peptide, mRNA or genomic DNA in the test sample.
• the presence of marker peptide, mRNA or genomic DNA in the test sample can be compared with information in a database or on a chart to result in detection or diagnosis.
• the methods further involve using a control biological sample obtained from the subject having periodontitis, wherein the control sample was obtained from the subject prior to the onset of periodontitis (i.e., when the subject was healthy or in a "normal", non- periodontitis state).
• the level of MMP-9 may be ascertained in vitro by contacting a cell with TNF ⁇ .
• a cell is a monocyte. After contacting a cell with TNF ⁇ , the level of MMP-9 is detected at either the protein or nucleic acid level.
• the level of MMP-9 is also ascertained in vitro by contacting a cell with TNF ⁇ in the presence of an antibacterial agent.
• the antibacterial agent is 2,4,4 ' - trichloro-2'-hydroxydiphenyl ether.
• agent is doxycycline.
• an agent may be something other than an antibacterial agent.
• an agent is an MMP inhibitor.
• a measure of down-regulation of MMP-9 by detecting the level of MMP-9 is ascertained in vitro by contacting a cell with TNF ⁇ in the presence of an agent, such as an antibacterial agent and comparing the level of MMP-9 ascertained in vitro by contacting a cell with TNF ⁇ in the absence of an antibacterial agent, wherein the experimental conditions are otherwise identical.
• an agent such as an antibacterial agent
• a lower level of MMP-9 protein, nucleic acid or enzymatic activity in the presence of antibacterial agent than in the absence of antibacterial agent is an indication that the antibacterial compound down-regulates MMP-9.
• an in vitro measure of down regulation of MMP-8, MMP-9 and/or MMP- 13 can be correlated to an in vivo effect, observation or result.
• down regulation of a metalloproteinase measured in vitro is a confirmation of an in vivo observation, including, but not limited to, treatment of periodontitis, a method of reducing a pathological excess of metalloproteinase and/or metalloproteinase activity in vivo, and a method of identifying a compound useful to treat periodontitis and/or reduce a pathological excess of metalloproteinase and/or metalloproteinase activity in vivo.
• down regulation of a metalloproteinase measured in vitro is a predictor of an in vivo result, including, but not limited to, treatment of periodontitis, a method of reducing a pathological excess of metalloproteinase and/or metalloproteinase activity in vivo, and a method of identifying a compound useful to treat periodontitis and/or reduce a pathological excess of metalloproteinase and/or metalloproteinase activity in vivo.
• the level of MMP- 13 may be ascertained in vitro by contacting a cell with parathyroid hormone (PTH).
• PTH parathyroid hormone
• a cell is an osteoblast.
• the level of MMP-13 is detected at either the protein or nucleic acid level.
• the level of MMP-13 is also ascertained in vitro by contacting a cell with PTH in the presence of an antibacterial agent.
• the antibacterial agent is 2,4,4'-trichloro-2'-hydroxydiphenyl ether.
• a lower level of MMP-13 protein, nucleic acid or enzymatic activity in the presence of antibacterial agent than in the absence of antibacterial agent is an indication that the antibacterial compound down-regulates MMP-13.
• an oral composition as set forth herein to treat periodontitis is ascertained by comparison of the effect of 2,4.4'-trichloro-2'-hydroxydiphenyl ether on metalloproteinase down regulation with the effect of the oral composition on metalloproteinase down regulation.
• the ability of any oral composition to treat periodontitis is ascertained by comparison of the effect of the oral composition, either in vivo or in vitro, with the effect of an oral composition as set forth herein.
• the invention further includes an oral composition, such as a dentifrice, gel, patch, mouthwash, or spray, among others, for use in a method of the invention.
• an oral composition comprises an antibacterial agent.
• the antibacterial agent is a noncationic antibacterial agent. See, for example, U.S. Pat. No. 5,288,480, which is hereby incorporated by reference in its entirety herein.
• the noncationic antibacterial agent is present in the oral composition in an effective antiplaque amount of 0.25-0.35% by weight, preferably 0.3%.
• the antibacterial agent is substantially water- insoluble, meaning that its solubility is less than 1 % by weight in water at 25 0 C and may be even less than 0.1%.
• the concentration of antibacterial agent may be reduced up to 10-fold over that which is used in another dentifrice, such as a toothpaste.
• the antibacterial agent is 2,4,4'- trichloro-2'-hydroxydiphenyl ether.
• the oral composition comprises two or more antibacterial agents.
• an antibacterial-enhancing agent enhances delivery of the antibacterial agent to, and retention thereof on oral surfaces.
• an AEA comprises an adherent material. See U.S. Pat. No. 5,288,480 for descriptions of materials and compositions useful for AEA materials of the present invention, as well as for general descriptions of oral compositions, such as dentifrice compositions, useful in the present invention.
• an adherent material in a composition is a polymer having a number average molecular weight between 100,000 and 2,500,000, inclusive.
• the adherent material is selected from polymers of polyvinyl phosphonic acid, poly (1-phosphonopropene) sulfonic acid, poly(beta styrene phosphonic acid), alpha styrene phosphonic acid, synthetic anionic polymeric polycarboxylate, maleic anhydride, maleic acid, and methyl vinyl ether.
• the adherent molecule is a polymer of methyl vinyl ether and maleic anhydride.
• An antibacterial-enhancing agent can be used at a level that is 0.01%-4.0% by weight of an oral composition.
• a "delivery-enhancing group” refers to one which attaches or substantively, adhesively, cohesively or otherwise bonds the AEA (carrying the antibacterial agent) to oral (e.g. tooth and gum) surfaces, thereby "delivering" the antibacterial agent to such surfaces.
• the organic retention-enhancing group generally hydrophobic, attaches or otherwise bonds the antibacterial agent to the AEA, thereby promoting retention of the antibacterial agent to the AEA and indirectly on the oral surfaces.
• attachment of the antibacterial agent occurs through physical entrapment thereof by the AEA, especially when the AEA is a cross-linked polymer, the structure of which inherently provides increased sites for such entrapment.
• an antibacterial-enhancing agent which enhances delivery and adherence of said antibacterial agent to, and the retention thereof on, oral tooth and gum surfaces is (i) a copolymer of maleic acid or anhydride with another inert ethylenically unsaturated polymerizable monomer or (ii) poly (beta-styrene-phosphonic acid) or poly (alpha-styrenephosphonic acid) polymer or a copolymer of either styrenephosphonic acid with another ethylenically unsaturated monomer.
• a copolymer of maleic acid or anhydride with another inert ethylenically unsaturated polymerizable monomer or
• poly (beta-styrene-phosphonic acid) or poly (alpha-styrenephosphonic acid) polymer or a copolymer of either styrenephosphonic acid with another ethylenically unsaturated monomer is (i) a copo
• an orally acceptable vehicle including a water-phase with humectant is present.
• Water is present typically an amount of at least 3% by weight, generally 3-35% and humectant, preferably glycerine and/or sorbitol, typically total 6.5-75% or 80% by weight of the dentifrice, more typically 10-75%.
• humectant preferably glycerine and/or sorbitol
• an additional ingredient which assists solubilization of the antibacterial agent in saliva may be incorporated in the water-humectant vehicle.
• Such optional solubilizing agents include humectant polyols such as propylene glycol, dipropylene glycol, and hexylene glycol, cellosolves such as methyl cellosolve and ethyl cellosolve, vegetable oils and waxes containing at least 12 carbons in a straight chain such as olive oil. castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
• humectant polyols such as propylene glycol, dipropylene glycol, and hexylene glycol
• cellosolves such as methyl cellosolve and ethyl cellosolve
• vegetable oils and waxes containing at least 12 carbons in a straight chain such as olive oil.
• castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
• propylene glycol includes
• polyethylene glycol 600 when present with triclosan in a weight ratio of 25 triclosan: l PEG 600 reduces the antibacterial activity of triclosan by a factor of 10-20 from that prevailing in the absence of the polyethylene glycol.
• the pH of an oral composition is generally in the range of 4.5 to 10 and in another aspect, 6.5 to 7.5. It is noteworthy that the compositions of the invention may be applied orally at a pH below 5 without substantially decalcifying or otherwise damaging dental enamel.
• the pH can be controlled with acid (e.g. citric acid or benzoic acid) or base (e.g. sodium hydroxide) or buffered (as with sodium citrate, benzoate, carbonate, or bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, etc.).
• Any abrasive particulates may be used and may be selected from sodium bicarbonate, calcium phosphate (e.g.,dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silica (e.g., hydrated silica), iron oxide, aluminium oxide, perlite, plastic particles, e.g., polyethylene, and combinations thereof.
• the abrasive may be selected from a calcium phosphate (e.g.,dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silica (e.g., hydrated silica), calcium pyrophosphate and combinations.
• silica any type of silica may be used, such as precipitated silicas or silica gels. Preferred are commercially available silicas such as INEOS AC43, available from Ineos Silicas, Warrington, United Kingdom. Other abrasives may also be used in accordance with the present invention. As set forth in U.S. Patent No. 4,358,437, powdered forms of calcium carbonate in an abrasive form constitute one important class of such abrasives. Examples of these abrasives are milled limestone or marble, chalks such as aragonite, calcite or mixtures thereof, and synthetically precipitated chalks such as waterworks chalk.
• an oral composition comprises a siliceous polishing agent.
• the polishing agent may be a siliceous material such as a hydrous silica gel, a silica xerogel or a complex amorphous alkali metal aluminosilicate or zirconosilicate or a precipitated silica.
• Colloidal silica materials include those sold under the trademark SYLOID such as those which have been sold as SYLOID 72 and SYLOID 74.
• Precipitated silicas include those sold under the trademark ZEODENT such as ZEODENT 1 13 and ZEODENT 1 15 and ZEODENT 1 19.
• a mouthwash or mouthrinse will generally not comprise an abrasive particulate or a polishing particulate.
• a patch will generally not comprise an abrasive particulate or a polishing particulate.
• An oral composition may also contain a source of fluoride ions, or fluorine-providing component, as anti-caries agent, in an amount sufficient to supply 25 ppm to 5,000 ppm of fluoride ions.
• a source of fluoride ions or fluorine-providing component, as anti-caries agent, in an amount sufficient to supply 25 ppm to 5,000 ppm of fluoride ions.
• fluoride ions or fluorine-providing component, as anti-caries agent
• inorganic fluoride salts such as soluble alkali metal, alkaline earth metal salts, or example, sodium fluoride, potassium fluoride, ammonium fluoride, calcium fluoride, a copper fluoride such as cuprous fluoride, zinc fluoride, barium fluoride, sodium flourosilicate, ammonium flourosilicate, sodium fluorozirconate, ammonium fluorozirconate, sodium monofluorophosphate, aluminum mono-and di-fluorophosphate, and fluorinated sodium calcium pyrophosphate.
• Alkali metal and tin fluorides such as sodium and stannous fluorides, sodium monofluorophosphate (MFP) and mixtures thereof, are preferred.
• this component is present in an amount up to 2% by weight, based on the weight of the preparation, and preferably in the range of 0.05% to 1%.
• the compound may be present in an amount of 0.1 -3%, and in an embodiment, 0.7-0.8%.
• a composition further comprises an agent selected from a stannous ion agent; a fluoride compound; sodium fluoride; chlorhexidine; alexidine; hexetidine; sanguinarine; benzalkonium chloride; salicylanilide; domiphen bromide; cetylpyridinium chloride (CPC); tetradecylpyridinium chloride (TPC); N-tetradecyl-4-ethylpyridinium chloride (TDEPC); octenidine; delmopinol; octapinol; nisin; zinc ion agent; copper ion agent; essential oils; furanones; bacteriocins, ethyllauroyl arginate, extracts of magnolia, a metal ion source, arginine, arginine bicarbonate, honokiol, magonol, ursolic acid, ursic acid, morin
• Some embodiments of the present invention provide methods of identifying a compound useful for treating a disease or condition of the oral cavity, the method comprising: obtaining a first gingival sample from a mammal suffering from a disease or condition of the oral cavity; obtaining a second gingival sample from the oral cavity of said mammal; contacting said first sample with a test compound; contacting said second sample with a positive control, wherein said positive control is a compound known to down-regulate the expression of one or more matrix metalloproteinases; measuring the extent to which the expression of one or more of said matrix metalloproteinases is down-regulated by said test compound; measuring the extent to which the expression of one or more of said matrix metalloproteinases is down-regulated by said positive control; and comparing the extent to which the expression of one or more of said matrix metalloproteinases is down-regulated by said test compound, with the extent to which the expression of one or more of said matrix metalloproteinases is down-regulated by said positive control; wherein
• the one or more matrix metal loproteinases are selected from the group consisting of: MMP-8, MMP-9, and MMP- 13.
• the positive control down-regulates the expression of MMP-8. MMP-9. and MMP-13.
• the disease or condition of the oral cavity is gingivitis or periodontitis.
• the positive control is a halogenated diphenylether. In yet other embodiments, the positive control is triclosan.
• test compound down-regulates the expression of one or more of said matrix metalloproteinases to a greater extent than said positive control. In further embodiments, the test compound down-regulates the expression of MMP-9, and
• test compound down-regulates the expression of MMP-8, MMP-9.
• the positive control down-regulates the expression of MMP-8.
• the positive control down-regulates the expression of MMP-9. In yet other embodiments, the positive control down-regulates the expression of MMP-13.
• U937 cells and RPMI 1640 culture medium were obtained from ATCC.
• Human MMP-9 ELISA Kit (QUANTIKINE) was obtained from R&D Systems.
• Fetal Bovine Serum (FBS) was obtained from VWR, and the penicillin-streptomycin solution and Tumor Necrosis Factor ⁇ (TNF ⁇ ) were obtained from Sigma.
• Table 1 Data for Figure 1 , demonstrating the effect of triclosan on MMP-9 production.
• Parathyroid hormone (rat PTH 1 -34) was purchased from Sigma.
• UMR 106-01 cells were cultured in Eagle's minimal essential medium (EMEM) supplemented with 25 mM Hepes pH 7.4, 1% nonessential amino acids, 100 units/ml penicillin, 100 ⁇ g/ml streptomycin. 5% fetal bovine serum.
• EMEM Eagle's minimal essential medium
• Real Time Quantitative RT-PCR was conducted according to the following method: UMR 106-01 cells were seeded in 12-well plates and cultured for 2-3 days in cell culture media. When cells were confluent, cell culture media was exchanged with 1% fetal bovine serum for overnight for cell starvation.
• cDNAs were amplified by adding 2.5 ⁇ l of cDNA to the PCR mixture (22.5 ⁇ l) containing each primer (0.2 ⁇ M) and 12.5 ⁇ l of the Platinum SYBR Green qPCR SuperMix UDG (Invitrogen). The reactions were preincubated at 50 0 C for 2 minutes to decontaminate dU-containing DNA by UDG, then at 95 0 C for 2 minutes to inactivate UDG and activate Taq. The PCR program continued 49 cycles of denaturation at 95 0 C for 15 seconds, annealing and elongation of the primers at 60 0 C for 30 seconds. Relative quantification of gene expression was determined by using the 2-delta delta CT method where fold changes in gene expression are relative to control samples. All samples were normalized to ⁇ -actin.
• UMR cells stimulated with PTH produced an increase in MMP- 13 expression.
• Triclosan at 10 ppm, 4 ppm and 1 ppm significantly reduced MMP-13 expression in PTH stimulated UMR cells.
• a triclosan-containing dentifrice slurry containing 10 ppm triclosan significantly reduced MMP- 13 expression in PTH stimulated UMR cells.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Microbiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42328354

Family Applications (1)

Country Status (20)

Families Citing this family (2)

Citations (6)

Family Cites Families (34)

• 2010
  • 2010-03-31 AR ARP100101094A patent/AR076177A1/es unknown
  • 2010-03-31 TW TW099109773A patent/TWI405565B/zh not_active IP Right Cessation
  • 2010-04-01 SG SG2011055332A patent/SG173487A1/en unknown
  • 2010-04-01 RU RU2011144028/15A patent/RU2524629C2/ru not_active IP Right Cessation
  • 2010-04-01 EP EP10712854.8A patent/EP2414838B1/en not_active Revoked
  • 2010-04-01 PL PL10712854T patent/PL2414838T3/pl unknown
  • 2010-04-01 JP JP2012503715A patent/JP5330596B2/ja not_active Expired - Fee Related
  • 2010-04-01 DK DK10712854.8T patent/DK2414838T3/da active
  • 2010-04-01 CN CN201080015649.0A patent/CN102365550B/zh not_active Expired - Fee Related
  • 2010-04-01 MY MYPI2011003577A patent/MY158406A/en unknown
  • 2010-04-01 MX MX2011008438A patent/MX2011008438A/es active IP Right Grant
  • 2010-04-01 WO PCT/US2010/029670 patent/WO2010115031A1/en active Application Filing
  • 2010-04-01 BR BRPI1013185A patent/BRPI1013185A2/pt not_active IP Right Cessation
  • 2010-04-01 AU AU2010232590A patent/AU2010232590B2/en not_active Ceased
  • 2010-04-01 ES ES10712854T patent/ES2432864T3/es active Active
  • 2010-04-01 CA CA2757317A patent/CA2757317C/en not_active Expired - Fee Related
  • 2010-04-01 US US13/262,027 patent/US8637266B2/en active Active
• 2011
  • 2011-08-17 ZA ZA2011/06054A patent/ZA201106054B/en unknown
  • 2011-09-06 CO CO11114807A patent/CO6420374A2/es not_active Application Discontinuation
• 2012
  • 2012-08-03 HK HK12107648.7A patent/HK1167272A1/xx not_active IP Right Cessation

Patent Citations (6)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events